Phenotypic characterization of the hematopoietic stem cell
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 24, 1998
Issued Date -
N/A
app pub date -
May 14, 1997
filing date -
May 1, 1990
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
One or more population of cells enriched for human hematopoietic stem cells is disclosed. HSC in this population of cells are capable of limited self-renewal and are capable of differentiating into all elements of the hematopoietic system. This population of cells has the phenotype of CD34.sup.+ /CD38.sup.- and more preferably CD34.sup.+ /CD38.sup.-/HLA-DR.sup.+. Cells within this population have been found to express CD13, CD33 and CD71. Hematopoietic stem cells can be used in a number of therapies, including autologous transplantation and in gene therapy.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully